Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01928095 · ClinicalTrials.gov registry record
RNA Cloning and Visualization in Human Atherosclerosis
A clinical trial, sponsored by University of Virginia.
- Completed
- Registry status
- 22
- Enrollment target
NCT01928095: Completed study, sponsored by University of Virginia.
NCT01928095 is a clinical trial that has completed, run by University of Virginia. The registered enrollment target is 22 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01928095 has completed, sponsored by University of Virginia.
- COMPLETED
- Registry status
- 22 participants
- Enrollment target
Study Summary
The research objectives of this project are as follows: 1. Obtain high-quality human atherosclerotic arterial samples from diseased donors. 2. Perform biochemical analysis to determine the abundance, localization and activity of Dicer and double-stranded RNAs in these diseased tissues.
Primary Outcome
The investigator will measure the relative levels of abundant canonical Dicer substrates/enzymatic products (i.e. the ratio of pre- to mature micro-RNA) via northern blot
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2013-10 |
| Est. Completion | 2016-11 |
What the finished NCT01928095 record still lists
NCT01928095 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 22 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01928095 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01928095 about?
NCT01928095 is a clinical study titled "RNA Cloning and Visualization in Human Atherosclerosis". The research objectives of this project are as follows: 1. Obtain high-quality human atherosclerotic arterial samples from diseased donors. 2. Perform biochemical analysis to determine the abundance, localization and activity of Dicer and double-stranded RNAs in these diseased tissues.
What is the current status of trial NCT01928095?
This trial is currently completed. The enrollment target is 22 participants. The study started on 2013-10. Estimated completion is 2016-11.
Who is sponsoring clinical trial NCT01928095?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia